Taro Pharmaceutical Industries Ltd.

DB:TAL Stock Report

Market Cap: €1.5b

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Taro Pharmaceutical Industries Past Earnings Performance

Past criteria checks 3/6

Taro Pharmaceutical Industries's earnings have been declining at an average annual rate of -15.7%, while the Pharmaceuticals industry saw earnings growing at 8.4% annually. Revenues have been declining at an average rate of 2.5% per year. Taro Pharmaceutical Industries's return on equity is 3%, and it has net margins of 8.6%.

Key information

-15.7%

Earnings growth rate

-15.1%

EPS growth rate

Pharmaceuticals Industry Growth7.3%
Revenue growth rate-2.5%
Return on equity3.0%
Net Margin8.6%
Last Earnings Update31 Mar 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Taro Pharmaceutical Industries makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

DB:TAL Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 246295423365
31 Dec 236114619860
30 Sep 235933321060
30 Jun 235752119257
31 Mar 235732519852
31 Dec 225704618951
30 Sep 225696516452
30 Jun 225719114653
31 Mar 225615811455
31 Dec 2156619556
30 Sep 2156889356
30 Jun 21578299360
31 Mar 21549-3879160
31 Dec 20576-3039859
30 Sep 20583-2689660
30 Jun 20601-2579659
31 Mar 206452449360
31 Dec 196502488864
30 Sep 196782749164
30 Jun 196772818663
31 Mar 196702829063
31 Dec 186653109063
30 Sep 186442348866
30 Jun 186552248869
31 Mar 186622118870
31 Dec 176832088770
30 Sep 177483308571
30 Jun 178074018867
31 Mar 178794578671
31 Dec 169484898671
30 Sep 169865388971
30 Jun 169695479275
31 Mar 169515419271
31 Dec 159305799275
30 Sep 159095329170
30 Jun 159485428865
31 Mar 158634858866
31 Dec 148064229255
30 Sep 147823959357
30 Jun 147363489358
31 Mar 147593619255
31 Dec 137373218754
30 Sep 137092948651
30 Jun 136652638747

Quality Earnings: TAL has a large one-off gain of $14.2M impacting its last 12 months of financial results to 31st March, 2024.

Growing Profit Margin: TAL's current net profit margins (8.6%) are higher than last year (4.4%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: TAL's earnings have declined by 15.7% per year over the past 5 years.

Accelerating Growth: TAL's earnings growth over the past year (111.7%) exceeds its 5-year average (-15.7% per year).

Earnings vs Industry: TAL earnings growth over the past year (111.7%) exceeded the Pharmaceuticals industry 1.5%.

Return on Equity

High ROE: TAL's Return on Equity (3%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/06/24 04:55
End of Day Share Price 2024/06/24 00:00
Earnings2024/03/31
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Taro Pharmaceutical Industries Ltd. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Randall StanickyGoldman Sachs
Raghuram SelvarajuH.C. Wainwright & Co.
Kenneth CacciatoreTD Cowen